Progestins in the menopause in healthy women and breast cancer patients.
At present, more than 200 progestin compounds are synthetized, but their biological effects are different: this is function of their structure, receptor affinity, metabolic transformations, the target tissues considered, dose. The action of progestins in breast cancer is controversial; some studies indicate an increase in breast cancer incidence, others show no differences, and yet others indicate a decrease. Many studies agree that treatment with progestins plus estrogens at a low dose and during a limited period (less than 5 years) can have beneficial effects in peri- and post-menopausal women. It was demonstrated that various progestins (e.g. nomegestrol acetate, medrogestone, promegestone), as well as tibolone and its metabolites, can block the enzymes involved in estradiol bioformation (sulfatase, 17beta-hydroxysteroid dehydrogenase) in breast cancer. Progesterone is converted into various metabolic products: in normal breast tissue the transformation is mainly to 4-ene derivatives, whereas in the tumor tissue 5alpha-pregane derivatives are predominant. Aromatase activity is the last step in the formation of estrogens by the conversion of androgens. In recent studies it was shown that 20alpha-dihydroprogesterone, a metabolite found mainly in normal breast tissue and having anti-proliferative properties, can act as an anti-aromatase agent. The data suggest the possible utilization of this compound in breast cancer prevention. In conclusion, in order to clarify and better understand the response of progestins in breast cancer (incidence and mortality), as well as in hormone replacement therapy or in endocrine dysfunction, new clinical trials are necessary using other progestins in function of the dose and period of treatment.
Pasqualini
Jorge R
JR
Hormones and Cancer Research Unit, Institut de Puériculture et de Périnatalogie, 26 Boulevard Brune, Paris, France. Jorge.Pasqualini@wanadoo.fr
D001940:Breast / Q000187:drug effects / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D004965:Estrogen Antagonists / Q000378:metabolism / Q000494:pharmacology; D004967:Estrogens / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D008593:Menopause / Q000502:physiology; D011374:Progesterone / Q000378:metabolism*; D045167:Progesterone Congeners / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D011372:Progestins / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use
D004965:Estrogen Antagonists; D004967:Estrogens; D045167:Progesterone Congeners; D011372:Progestins; D011374:Progesterone